Brainomix Secures £4.8 Million to Transform Stroke and Lung Disease Care in the US
In an exciting development within the healthcare technology sector, Brainomix, a pioneering AI imaging provider, has recently announced a £4.8 million extension to its Series C financing round. This funding aims to bolster its expansion efforts in the United States, particularly in stroke and lung fibrosis care.
AI Imaging Solutions Paving the Way for Enhanced Patient Care
The University of Oxford spinout is not a newcomer to the scene; its initial Series C funding of £14 million in March 2025 brought its total funding round to nearly £19 million. This financial backing underscores growing investor confidence in Brainomix's transformative technologies, designed to improve clinical decision-making and patient outcomes. As co-founder and CEO Dr. Michalis Papadakis noted, “Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time.”
Bridging the Gap in Patient Triage
With its advanced platforms, Brainomix 360 Stroke and e-Lung, the company aims to revolutionize how clinicians diagnose and treat stroke patients and individuals suffering from lung diseases. Recent studies published in The Lancet Digital Health highlight how the Brainomix 360 Stroke imaging tool has already been deployed in over 70 NHS hospitals, enabling doctors to identify critical clots in stroke patients over an hour earlier than traditional methods.
Strength in Investment: New Ventures Supporting Expansion
The latest funding round was led by established investors Parkwalk Advisors and Hostplus, along with new partners like Modi Ventures, which adds strength to Brainomix's financial backing. Sahir Ali, founder and general partner of Modi Ventures, emphasized the significance of Brainomix's clinical validation and real-world evidence supporting its technologies. He stated, “Brainomix has built an exceptionally strong platform backed by rigorous clinical validation and real-world evidence.”
Future Predictions and Implications for Health Care Leaders
The ability to leverage AI technology in real-world applications will inevitably reshape healthcare delivery in the coming years, particularly in settings like primary stroke centers. As knowledge about AI tools like Brainomix 360 Stroke continues to spread, healthcare leaders need to consider how they might adopt these innovations in their practices to ensure timely and effective patient care.
Considerations for Health Care Providers
As Brainomix prepares to enhance support for its customers across the US and Europe, health care leaders should take note of the broader implications of integrating such technologies. These advancements promise not only to improve patient journeys but also to streamline systems within hospitals. Leaders are encouraged to explore how adopting similar innovations can elevate their organization’s efficiency and quality of care.
Add Row
Add
Write A Comment